Drugs / 99mTc-NM-02
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04674722 | Aug 2020 → May 2024 | breast cancer | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase 0 | NCT04040686 | Jul 2019 → Dec 2021 | breast cancer | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 99m-Tc-NM-02 | “Technetium-99m Labeled Anti-HER2 sdAb (99m-Tc-NM-02) for HER2 Expression Detection in Breast Cancer” NCT04040686 ↗ |
| Modality | Protein / enzyme biologic | “a novel 99mTc-labeled anti-HER2 single-domain antibody (99mTc-NM-02) as a molecular imaging tracer” PMID 34328338 ↗ Jul 2021 |
| Route | Other | “in a single dose injection” NCT04040686 ↗ |